At close: December 20 at 4:00:01 PM EST
After hours: December 20 at 4:11:56 PM EST
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Someit Sidhu M.D. | Founder & Director | 547.51k | -- | 1989 |
| Mr. Verender S. Badial | Chief Financial Officer | 462k | -- | 1972 |
| Ms. Kimberly Ann Davis | Chief Legal Officer & Corporate Secretary | 706.69k | -- | 1968 |
| Mr. Robert Lisicki | CEO & Director | -- | -- | 1967 |
| Dr. Gary Whale Ph.D. | Chief Technology Officer | -- | -- | 1974 |
| Ms. Theresa Lowry | Chief Human Resources Officer | -- | -- | 1974 |
| Mr. David Brady | Head of Business Development | 125.05k | -- | -- |
| Dr. Kiran Nistala MBBS, Ph.D. | Chief Medical Officer & Head of Development | -- | -- | 1973 |
Zura Bio Limited
1489 W. Warm Springs Road
Suite 110
Henderson, NV 89014
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Corporate Governance
Zura Bio Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 7, 2024 at 11:30 AM UTC
Zura Bio Limited Earnings Date
Recent Events
Related Tickers
CGEM Cullinan Therapeutics, Inc.
11.60
+5.94%
CRGX CARGO Therapeutics, Inc.
14.90
+10.29%
CLYM Climb Bio, Inc.
1.9500
0.00%
TYRA Tyra Biosciences, Inc.
14.00
-3.45%
PASG Passage Bio, Inc.
0.6600
+0.92%
UPB Upstream Bio, Inc.
16.21
-2.41%
PEPG PepGen Inc.
3.6300
-11.25%
FHTX Foghorn Therapeutics Inc.
5.14
+3.21%
TRML Tourmaline Bio, Inc.
20.65
+1.52%
CMPX Compass Therapeutics, Inc.
1.3800
+0.73%